Bayer's China Green Light for Sunharbo Is a Milestone, Not Yet a Revenue Line

Bayer has secured the world's first regulatory approval for a factor XIa inhibitor — but the distinction between a scientific milestone and a commercial one sits at the heart of how investors should read a busy week of pipeline news from the German drugs-to-seeds group.

China's NMPA cleared Asundexian, to be marketed as Sunharbo, on Monday for reducing stroke risk in adults who have suffered a non-cardioembolic ischemic stroke or a high-risk transient ischemic attack. Bayer, which based the filing on its Phase III OCEANIC-STROKE trial, described the compound as the first FXIa inhibitor approved anywhere in the world. Bloomberg flagged the Chinese decision as one of several pending catalysts for the company, noting that a US approval has yet to materialise.

The geographic and clinical scope of that clearance matters. It covers China and the specific patient groups named on the label — it does not imply approvals elsewhere or broader use. Even investors who see substantial promise in the mechanism should hold that boundary in place.

Prostate data draw the buyers

Darolutamide, sold as Nubeqa, delivered the week's other headline. Bayer reported on Saturday that an interim analysis of the Phase III DASL-HiCaP trial in high-risk prostate cancer patients showed a 58% reduction in the combined primary endpoint of metastases or death. The four-year metastasis-free survival rate came in at 95% versus 88% for placebo. Both arms received androgen deprivation therapy and radiotherapy alongside the study drug.

Should investors sell immediately? Or is it worth buying Bayer?

Reuters reported that Bayer shares drew buyers on Monday following the release. JPMorgan analyst Richard Vosser took a positive view of the interim results, keeping an "Overweight" rating and a EUR 61 price target, according to media reports.

Worth keeping in view: darolutamide is not currently approved for the treatment setting examined in DASL-HiCaP. The data are an interim readout, and the gap between a promising result and a label extension is precisely where expectations can outrun reality. Treating a possible additional indication as an assured business contribution is the risk investors carry here.

Kidney subgroup data round out the week

Bayer added a third clinical update on Thursday, with new subgroup analyses from the Phase III FIND-CKD study of finerenone. According to the company, the data showed consistent effects on proteinuria and on decline in kidney function among patients with chronic kidney disease without diabetes.

The next scheduled marker on the corporate calendar is November 3, 2026, when Bayer publishes its third-quarter 2026 statement, alongside an investor video conference and a media briefing.

What the two paths actually offer

The constructive case does not require equating the two developments. They could complement each other: Asundexian already holds a Chinese approval, while darolutamide opens a possible additional treatment avenue. Together they could broaden the base for future business opportunities — provided the Chinese clearance translates into economically meaningful use, and provided the prostate results eventually support an expanded label. Neither is a given.

Bayer at a turning point? This analysis reveals what investors need to know now.

The bearish counterargument is not aimed at the science but at its potential overvaluation. Jumping straight from clinical efficacy to future profits skips the distance between a trial result, an approval and commercial traction. Likewise, the "world's first approved FXIa inhibitor" label describes a regulatory advance; on its own it establishes neither a particular level of demand nor a fixed economic outcome.

The next concrete regulatory catalyst would be a decision on darolutamide in the studied setting — a positive outcome there would materially change its status relative to today's data. Until then, the potential extra business belongs in the opportunity column, not the banked column. For Asundexian, the verdict will rest on whether the approval granted this week acquires commercial weight.

Ad

Bayer Stock: New Analysis - 28 October

Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Bayer analysis...